Annexon biosciences completes enrollment in archer phase 2 trial of novel c1q inhibitor, anx007, in patients with geographic atrophy

Topline efficacy and safety data expected in first half of 2023 topline efficacy and safety data expected in first half of 2023

ANNX Ratings Summary

ANNX Quant Ranking